2024年10月8日早盘,嘉和生物-B(06998)股价出现大幅波动,早盘一度下跌5.13%,报2.22港元,引起市场广泛关注。
根据相关消息,这一股价大跌的主要原因是嘉和生物公告将与亿腾医药(一家从事抗感染、心血管和呼吸领域原研药研发的生物制药公司)进行合并。根据合并协议,此次合并将采取换股方式进行,构成反向收购,合并完成后亿腾医药实控人将成为新公司的控股股东。
此次合并旨在借助亿腾医药的商业化能力来加速推进嘉和生物旗下CDK4/6i引物的商业化进程。虽然嘉和生物一直未有重磅产品上市,但与亿腾医药的合作或将为其带来转机。未来,新公司将致力于肿瘤学及免疫性疾病领域的创新药物研发和商业化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.